

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/261300 A1

- (51) **International Patent Classification:**
C12N 15/79 (2006.01) *C12N 15/113* (2010.01)
C12N 15/67 (2006.01) *A61K 31/7105* (2006.01)
- (21) **International Application Number:**
PCT/EP2024/067532
- (22) **International Filing Date:**
21 June 2024 (21.06.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
23180698.5 21 June 2023 (21.06.2023) EP
- (71) **Applicant:** **SRTD BIOTECH** [DE/DE]; Huthmacherstrasse 20, 52428 Jülich (DE).
- (72) **Inventor:** **HOFFMANN, Bernd**; c/o SRTD BIOTECH, Huthmacherstrasse 20, 52428 Jülich (DE).
- (74) **Agent:** **KUTTENKEULER, David**; SKM-IP PartGmbB, Oberanger 45, 80331 Munich (DE).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) **Title:** CELL SPECIFIC TRANSLATION OF RNA MOLECULES

FIGURE 1



(57) **Abstract:** [1] The invention provides an improved RNA construct that allows for a target cell specific translation of a protein of interest in eukaryotic cells. The invention applies RNA constructs that are introduced directly into eukaryotic cells, and which are only translated into a protein in the presence of a specific trigger RNA sequence. The invention allows for a controlled expression of proteins or any proteinaceous antigen in target cells. The invention is useful for medical applications such as RNA based vaccination approaches to restrict antigen expression to target tissues.